To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:7 Number:609 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
Author Verified
RCT
ACE Report #5094
Ace Report Cover Tumour

Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma


How to Cite

OrthoEvidence. Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma. ACE Report. 2013;2(7):609. Available from: https://myorthoevidence.com/AceReport/Report/5094

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1

J Clin Oncol. 2012 Jun 10;30(17):2112-8. doi: 10.1200/JCO.2011.38.4420. Epub 2012 May 7

Contributing Authors:
S Ferrari P Ruggieri G Cefalo A Tamburini R Capanna F Fagioli A Comandone R Bertulli G Bisogno E Palmerini M Alberghini A Parafioriti A Linari P Picci G Bacci

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

246 patients with nonmetastatic osteosarcoma were randomized to evaluate the addition of ifosfamide to a primary chemotherapy regimen of methotrexate, cisplatin, and doxorubicin, with patients allocated to chemotherapy with or without ifosfamide. After a median follow-up of 76 months, there was no difference between groups in overall survival, event-free survival, and the percentage of patients wi...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.